CN103562223B - 抗c‑Met抗体 - Google Patents

抗c‑Met抗体 Download PDF

Info

Publication number
CN103562223B
CN103562223B CN201180052993.1A CN201180052993A CN103562223B CN 103562223 B CN103562223 B CN 103562223B CN 201180052993 A CN201180052993 A CN 201180052993A CN 103562223 B CN103562223 B CN 103562223B
Authority
CN
China
Prior art keywords
antibody
sequence
human
seq
met
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180052993.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN103562223A (zh
Inventor
安娜·胡尔特贝里
迈克尔·桑德斯
乔纳斯·德哈德
艾丽斯·费斯特延斯
纳塔利·德扬
保罗·米基耶利
克里斯蒂娜·巴西利科
托尔斯滕·德赖尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alkings Co
ArgenX SE
Original Assignee
ArgenX SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ArgenX SE filed Critical ArgenX SE
Publication of CN103562223A publication Critical patent/CN103562223A/zh
Application granted granted Critical
Publication of CN103562223B publication Critical patent/CN103562223B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201180052993.1A 2010-11-03 2011-11-03 抗c‑Met抗体 Active CN103562223B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40986610P 2010-11-03 2010-11-03
US61/409,866 2010-11-03
PCT/EP2011/069369 WO2012059561A1 (en) 2010-11-03 2011-11-03 Anti c-met antibodies

Publications (2)

Publication Number Publication Date
CN103562223A CN103562223A (zh) 2014-02-05
CN103562223B true CN103562223B (zh) 2017-02-22

Family

ID=44906140

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201180052993.1A Active CN103562223B (zh) 2010-11-03 2011-11-03 抗c‑Met抗体
CN201180063338.6A Pending CN103764678A (zh) 2010-11-03 2011-11-03 c-Met抗体组合

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201180063338.6A Pending CN103764678A (zh) 2010-11-03 2011-11-03 c-Met抗体组合

Country Status (12)

Country Link
US (7) US9688773B2 (OSRAM)
EP (3) EP2635603B1 (OSRAM)
JP (3) JP5857060B2 (OSRAM)
CN (2) CN103562223B (OSRAM)
AU (3) AU2011325097B2 (OSRAM)
BR (3) BR122014027420A2 (OSRAM)
CA (2) CA2816919A1 (OSRAM)
DK (1) DK2635602T3 (OSRAM)
ES (1) ES2594493T3 (OSRAM)
IL (2) IL226112B (OSRAM)
RU (2) RU2608644C2 (OSRAM)
WO (2) WO2012059562A1 (OSRAM)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8444976B2 (en) * 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
EP2143441A1 (en) 2008-07-08 2010-01-13 Pierre Fabre Medicament Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer
BR122014027420A2 (pt) 2010-11-03 2019-08-20 Argenx Bvba Anticorpos anti c-met
KR20130036993A (ko) * 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
EP2768857B1 (en) * 2011-10-19 2020-01-01 NovImmune SA Methods of purifying antibodies
EP2773660A2 (en) * 2011-11-03 2014-09-10 Argen-X B.V. Chimeric human-camel antigens and their use
BR112014012005A2 (pt) 2011-11-21 2017-12-19 Genentech Inc composições, métodos, formulação farmacêutica e artigo
WO2013079973A1 (en) * 2011-12-02 2013-06-06 Di Cara Danielle Marie Antibodies against hgf - receptor and uses
EP2807189B1 (en) 2012-01-23 2019-03-20 Ablynx N.V. Sequences directed against hepatocyte growth factor (hgf) and polypeptides comprising the same for the treatment of cancers and/or tumors
EP2708556B1 (en) * 2012-09-12 2018-11-07 Samsung Electronics Co., Ltd Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
US9535055B2 (en) * 2013-03-28 2017-01-03 Samsung Electronics Co., Ltd. Marker for determining effects of anti-c-Met antibody and method of determining effects of anti-c-Met antibody using the marker
EP2786765B1 (en) 2013-04-01 2018-10-03 Samsung Electronics Co., Ltd. Composition for combination therapy comprising an anti-C-met antibody and a FGFR inhibitor
KR102139607B1 (ko) * 2013-04-01 2020-07-30 삼성전자주식회사 항 c-Met 항체 및 FGFR 저해제를 포함하는 병용 투여용 약학 조성물
US10214593B2 (en) 2013-04-02 2019-02-26 Samsung Electronics Co., Ltd. Anti-idiotype antibody against anti-c-MET antibody
KR102060540B1 (ko) 2013-04-03 2019-12-31 삼성전자주식회사 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물
US9994644B2 (en) 2013-04-30 2018-06-12 Agency For Science, Technology And Research mAB 2 anti-Met antibody
KR102186363B1 (ko) * 2013-09-06 2020-12-04 삼성전자주식회사 c-Met 저해제 및 베타-카테닌 저해제를 포함하는 병용 투여용 약학 조성물
KR102192591B1 (ko) * 2013-09-09 2020-12-18 삼성전자주식회사 c-Met 저해제 및 c-Myc 저해제를 포함하는 병용 투여용 약학 조성물
EP3800270B1 (en) * 2014-07-29 2021-10-27 Wellmarker Bio Co., Ltd. Inhibitors of met and igsf1 for treating gastric and lung cancer
KR102200274B1 (ko) * 2014-09-16 2021-01-08 심포젠 에이/에스 항-ｍｅｔ 항체 및 조성물
US20180057595A1 (en) * 2015-03-16 2018-03-01 Celldex Therapeutics, Inc. Anti-MET Antibodies and Methods of Use Thereof
GB201611123D0 (en) * 2016-06-27 2016-08-10 Euremab Srl Anti met antibodiesand uses thereof
EP3515936A1 (en) 2016-09-23 2019-07-31 Elstar Therapeutics, Inc. Multispecific antibody molecules comprising lambda and kappa light chains
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
WO2018221969A1 (en) * 2017-05-30 2018-12-06 Chong Kun Dang Pharmaceutical Corp. A novel anti-c-met antibody and use thereof
RU2751720C2 (ru) 2017-05-30 2021-07-16 Чонг Кун Данг Фармасьютикал Корп. Новое анти-с-мет антитело и его применение
KR102869563B1 (ko) 2017-07-17 2025-10-10 얀센 바이오테크 인코포레이티드 피브로넥틴 iii형 도메인에 대한 항원 결합 영역 및 이의 사용 방법
CN109771642B (zh) * 2017-11-13 2022-09-20 同济大学苏州研究院 c-MET激动型抗体及其用途
AU2019349651B2 (en) * 2018-09-27 2023-12-07 Celgene Corporation SIRP alpha binding proteins and methods of use thereof
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
CN114340684B (zh) 2019-09-16 2025-09-12 瑞泽恩制药公司 用于免疫pet成像的放射性标记的met结合蛋白
WO2022214517A1 (en) 2021-04-08 2022-10-13 Byondis B.V. Anti-c-met antibodies and antibody-drug conjugates
TW202328188A (zh) * 2021-09-03 2023-07-16 美商Ｇｏ治療公司 抗醣化-cmet抗體及其用途
AU2024277829A1 (en) 2023-05-19 2025-12-04 Les Laboratoires Servier Anti-met antibodies, antibody-drug conjugates, compositions and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009007427A2 (en) * 2007-07-12 2009-01-15 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5648273A (en) 1989-12-27 1997-07-15 The United States Of America, As Represented By The Department Of Health And Human Services Hepatic growth factor receptor is the MET proto-oncogene
DE69334159D1 (de) 1992-09-18 2007-09-13 Us Gov Health & Human Serv Medizinische Verwendung eines Antikörpers oder eines Antikörperfragments gegen die extrazelluläre Domäne von Met zur Prevention von Metastasen
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
JP2000515735A (ja) 1996-07-03 2000-11-28 ジェネンテック インコーポレーテッド 肝細胞成長因子レセプターアゴニスト
ITMI20031127A1 (it) 2003-06-05 2004-12-06 Uni Degli Studi Del Piemont E Orientale Am Anticorpi anti-hgf-r e loro uso
CN100538364C (zh) * 2003-06-06 2009-09-09 健泰科生物技术公司 调节HGFβ链和C-MET的相互作用
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
KR100556660B1 (ko) * 2003-11-11 2006-03-10 국립암센터 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
CN1922208A (zh) 2003-12-11 2007-02-28 健泰科生物技术公司 用于抑制c－met二聚化及活化的方法和组合物
ME01803B (me) 2004-08-05 2010-12-31 Genentech Inc Humanizovani anti-cmet antagonisti
WO2007110698A2 (en) 2005-11-16 2007-10-04 Fariba Nayeri Methods for inhibiting carcinogenesis and/or metastasis in an individual with endogenous c-met ligands and inhibitors
US8388958B2 (en) 2006-02-06 2013-03-05 Metheresis Translational Research Sa Anti-MET monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products
CN103183738B (zh) * 2006-03-30 2014-08-06 诺瓦提斯公司 c-Met抗体的组合物和使用方法
FR2906533B1 (fr) 2006-09-28 2013-02-22 Pf Medicament Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations
EP2177623A4 (en) 2007-07-19 2010-12-29 Eisai R&D Man Co Ltd SCREENING METHOD USING C-MET, A NEW SUBSTRATE FOR GAMMA SECRETASE
US7892770B2 (en) 2007-08-24 2011-02-22 Van Andel Research Institute Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methods
IL198545A0 (en) 2008-05-14 2011-07-31 Metheresis Translational Res Sa High affinity binding site of hgfr and methods for identification of antagonists thereof
US8455623B2 (en) 2008-05-21 2013-06-04 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
WO2009145606A1 (en) 2008-05-28 2009-12-03 U-Protein Express B.V. Method for the production of proteins or protein fragments
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
WO2010005965A1 (en) 2008-07-08 2010-01-14 Aronchick Craig A Colonic purgative formulations and methods of using the same
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
AR074439A1 (es) 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)
US8545839B2 (en) 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
BR122014027420A2 (pt) 2010-11-03 2019-08-20 Argenx Bvba Anticorpos anti c-met

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009007427A2 (en) * 2007-07-12 2009-01-15 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met.;Basilico C et al.;《J Biol Chem.》;20080521;第283卷(第30期);第21267-21277页 *

Also Published As

Publication number Publication date
US9688773B2 (en) 2017-06-27
WO2012059562A1 (en) 2012-05-10
CA2816745C (en) 2019-03-12
RU2608644C2 (ru) 2017-01-23
BR122014027420A2 (pt) 2019-08-20
US9688774B2 (en) 2017-06-27
US9631027B2 (en) 2017-04-25
US8637027B2 (en) 2014-01-28
CA2816919A1 (en) 2012-05-10
CA2816745A1 (en) 2012-05-10
RU2013125459A (ru) 2014-12-10
US20150376291A1 (en) 2015-12-31
DK2635602T3 (en) 2016-10-10
WO2012059561A1 (en) 2012-05-10
AU2011325098B2 (en) 2016-07-14
JP2013545738A (ja) 2013-12-26
EP3165538A1 (en) 2017-05-10
IL226112B (en) 2019-05-30
AU2011325097B2 (en) 2015-05-21
AU2015210420A1 (en) 2015-09-03
AU2011325098A1 (en) 2013-05-09
AU2011325097A1 (en) 2013-05-02
EP2635603A1 (en) 2013-09-11
US9884917B2 (en) 2018-02-06
IL226113A0 (en) 2013-06-27
JP2013545455A (ja) 2013-12-26
US20180215833A1 (en) 2018-08-02
BR112013010688B1 (pt) 2020-11-17
IL226112A0 (en) 2013-06-27
US10676535B2 (en) 2020-06-09
JP5857060B2 (ja) 2016-02-10
JP2016034957A (ja) 2016-03-17
CN103562223A (zh) 2014-02-05
CN103764678A (zh) 2014-04-30
AU2015210420B2 (en) 2017-08-03
BR112013010687A2 (pt) 2016-08-02
US20170349667A1 (en) 2017-12-07
ES2594493T3 (es) 2016-12-20
US20120156206A1 (en) 2012-06-21
EP2635602A1 (en) 2013-09-11
RU2013125457A (ru) 2014-12-10
US20120148607A1 (en) 2012-06-14
EP2635603B1 (en) 2016-03-23
BR112013010688A2 (pt) 2016-08-09
US20140205606A1 (en) 2014-07-24
EP2635602B1 (en) 2016-09-07
US20150376292A1 (en) 2015-12-31

Similar Documents

Publication Publication Date Title
CN103562223B (zh) 抗c‑Met抗体
JP6261651B2 (ja) Ｃｄ７０に対する抗体
JP7163275B2 (ja) 抗－ｉｌ－２２ｒ抗体
Anna et al. Anti C-met Antibodies-granted patent (Canada)

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Holland Breda

Applicant after: ARGEN-X B.V.

Address before: Holland Breda

Applicant before: ARGEN-X B.V.

COR Change of bibliographic data
C14 Grant of patent or utility model
GR01 Patent grant
CP01 Change in the name or title of a patent holder

Address after: Holland Breda

Patentee after: Alkings Co.

Address before: Holland Breda

Patentee before: ARGEN-X B.V.

CP01 Change in the name or title of a patent holder
TR01 Transfer of patent right

Effective date of registration: 20180118

Address after: Belgium zwijnaarde

Patentee after: ARGEN-X B.V.

Address before: Holland Breda

Patentee before: Alkings Co.

TR01 Transfer of patent right